| Typicality: | 0.577 |
| Saliency: | 0.500 |
| after human trial | 11 | temporal |
| in 2002 | 7 | temporal |
| each year | 6 | temporal |
| drug → enter → the market | 113 |
| drug → be entered → the market | 6 |
| drug → enter → market | 3 |
| drug → entered → the market | 3 |
| drug → enter into → the market | 3 |
| negative | neutral | positive |
| 0.242 | 0.612 | 0.146 |
| Raw frequency | 128 |
| Normalized frequency | 0.500 |
| Modifier score | 0.850 |
| Perplexity | 310.023 |